Latest KFF Health News Stories
Podcast: KHN’s ‘What The Health?’ Falling Premiums And Rising Political Tensions
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
No More Secrets: Congress Bans Pharmacist ‘Gag Orders’ On Drug Prices
Congress approved two bills last month that prohibit provisions keeping pharmacists from telling patients when they can save money by paying the cash price instead of the price negotiated by their insurance plan.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
In The Battle To Control Drug Costs, Old Patent Laws Get New Life
Health insurers and pharmacy benefit managers are exploring how two legal provisions — which have been on the books for decades — could bring down the price tags of certain prescription medications.
Podcast: KHN’s ‘What The Health?’ Some Things Old, Some Things New
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ (Almost) Live from Austin!
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Ollstein of Politico talk about how health issues will play in midterm elections, the Trump administration’s move that could penalize legal immigrants who use government aid programs, and other topics. Due to technical difficulties, the original discussion taped Sept. 27 at the 2018 Texas Tribune Festival could not be broadcast, so the panelists reconvened from Austin and Washington on Sept. 28.
Buried In Congress’ Opioid Bill Is Protection For Personal Drug Imports
The protection is a win for people who get their needed, legitimate drugs from overseas.
Readers And Tweeters Slice And Dice Precision Medicine, Step Therapy
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
As States Try To Rein In Drug Spending, Feds Slap Down One Bold Medicaid Move
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren’t proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
New Medicare Advantage Tool To Lower Drug Prices Puts Crimp In Patients’ Choices
Federal officials are allowing the private insurance plans to use “step therapy” for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
El alto precio de la insulina lleva a que pacientes la racionen, a riesgo de muerte
El precio de la insulina en los Estados Unidos aumentó más del doble desde 2012. Eso pone a la hormona que salva vidas fuera del alcance de algunas personas con diabetes.
Insulin’s Steep Price Leads To Deadly Rationing
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
The High Cost Of Hope: When The Parallel Interests Of Pharma And Families Collide
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
Legisladores presionan para proteger a los pacientes y llevarle la contra a Trump
Los legisladores de California jugaron ataque y defensa este año en el tema de salud, promulgando proyectos para ampliar el acceso a la vez que desafiando a las normas de Trump.
